SEC Comment Letter for Cannagistics Inc. (CIK 0001304741) — Dec 21, 2021
Cannagistics Inc. (CIK 0001304741)
Date: Dec. 21, 2021 · CIK: 0001304741 · Accession: 0000000000-21-015219
AI Filing Summary & Sentiment
Show Raw Text
United States securities and exchange commission logo
December 21, 2021
James Zimbler
Vice President of Corporate Finance
Cannagistics Inc.
150 Motor Parkway
Suite 401
Hauppauge, NY 11787
Re:Cannagistics Inc.
Form 10-K for the fiscal year ended July 31, 2021
Filed November 4, 2021
File No. 0-55711
Dear Mr. Zimbler:
We have reviewed your filing and have the following comments.
Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
Form 10-K for the fiscal year ended July 31, 2021
Controls and Procedures, page 28
1.You disclose that "management concluded that, as of July 31, 2020, our internal control
over financial reporting was not effective." Please amend your form 10-K to instead state,
if true, that such conclusion was made as of July 31, 2021.
2.Regarding the steps listed to remediate such weaknesses in your internal control over
financial reporting, you state that you "hope to implement the following changes during
our fiscal year ending July 31, 2020". Please revise the foregoing date as deemed
appropriate since the foregoing period has already ended.
FirstName LastNameJames Zimbler
Comapany NameCannagistics Inc.
December 21, 2021 Page 2
FirstName LastName
James Zimbler
Cannagistics Inc.
December 21, 2021
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
You may contact Jenn Do at (202) 551-3743 or Mary Mast at (202) 551-3613 if you have
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences